App-Quantinova.ai

Perceived disease severity and treatment satisfaction among patients with ulcerative colitis in Europe

A Armuzzi - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Disease duration in Crohn’s disease is a strong determinant for having a colectomy in geriatric population

H Htet - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Mucosal healing (MH) assessed with PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) and probe Confocal Laser Endomicroscopy (pCLE) do not reflect histological normalisation using the ECAP (Extent Chronicity Activity Plus) score

M Iacucci - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Clinical validation of a blood-based prognostic biomarker in Inflammatory bowel disease; towards personalised medicine in IBD

P Lyons - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Methadone hydrochloride

Day of admission results predict failure of first-line treatment in acute ulcerative colitis

R Grant - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Cyclosporine A

How useful are blood tests in the diagnosis of paediatric inflammatory bowel disease?

J J Ashton - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Long-term bowel function and fate of the ileal pouch after restorative proctocolectomy in patients with Crohn’s disease: a systematic review and meta-analysis

G Pellino - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Re-defining the concept of endoscopic and histological healing by using electronic virtual chromoendoscopy and probe confocal endomicroscopy in ulcerative colitis

M Iacucci - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Fluorescein sodium

Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib

S Danese - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

ABT-494

Faecal calprotectin identifies microscopic inflammation in ulcerative colitis patients with complete endoscopic healing: a post-hoc analysis of the MOMENTUM trial

T W Stevens - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Mesalamine

Prevalence and factors associated with impaired food-related quality of life: a cross-sectional survey of 1223 people with inflammatory bowel disease

W Czuber-Dochan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Inflammatory bowel disease

N/A

Rates of wound healing in patients with Crohn’s disease undergoing proctectomy

R Grant - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres

V Cheung - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Pembrolizumab

Responder definitions for the ulcerative colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) tool using patients with ulcerative colitis treated with etrolizumab

P Higgins - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Etrolizumab

Magnetic resonance enterograghy in operative planning for patients with Crohn’s disease of the small bowel: does timing matter?

A Patel - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Detection and monitoring of IBD based on faecal volatile organic compounds

S Bosch - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Telephone straight-to-test (tSTT) improves early diagnosis of inflammatory bowel disease (IBD)

H Htet - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

The emotional impact of diagnosis on patients with ulcerative colitis in the UK

C McMullan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Real-world use of the IBD Disk tool for evaluation of patient-reported disability in the outpatient clinic

E Savelkoul - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease

G Walker - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Filters

45280 Abstracts